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ABSTRACT 
Objectives: The spectrum of antinuclear antibodies (ANA) is changing to include both nuclear 
staining as well as cytoplasmic and mitotic cell patterns (CMPs) and accordingly a change in 
terminology to anti-cellular antibodies. This study examined the prevalence of indirect 
immunofluorescence (IIF) anti-cellular antibody staining using the Systemic Lupus International 
Collaborating Clinics inception cohort.  
Methods:  Anti-cellular antibodies were detected by IIF on HEp-2000 substrate utilizing the baseline 
serum. Three serological subsets were examined: 1) ANA-positive (presence of either nuclear or 
mixed nuclear/CMP staining), 2) anti-cellular antibody-negative (absence of any intracellular 
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staining), and 3) isolated CMP staining. The odds of being anti-cellular antibody-negative versus ANA 
or isolated CMP-positive was assessed by multivariable analysis.  
Results: 1137 patients were included; 1049/1137 (92.3%) were ANA-positive, 71/1137 (6.2%) were 
anti-cellular antibody-negative, and 17/1137 (1.5%) had isolated CMP.  The isolated CMP group did 
not differ from the ANA-positive or anti-cellular antibody-negative group in clinical, demographic or 
serologic features. Patients who were older (OR 1.02 [95% CI: 1.00, 1.04]), of Caucasian 
race/ethnicity (OR 3.53 [95% CI: 1.77, 7.03]), or on high dose glucocorticoids at or prior to enrolment 
(OR 2.39 [95% CI: 1.39, 4.12]) were more likely to be anti-cellular antibody-negative. Patients on 
immunosuppressants (OR 0.35 [95% CI: 0.19, 0.64]) or with anti-SSA/Ro60 (OR 0.41 [95% CI: 0.23, 
0.74]) or anti-UI-RNP (OR 0.43 [95% CI: 0.20, 0.93]) were less likely to be anti-cellular antibody-
negative.  
Conclusions: In newly diagnosed SLE, 6.2% of patients were anti-cellular antibody-negative and 1.5% 
had isolated CMP. The prevalence of anti-cellular antibody-negative SLE will likely decrease as 
emerging nomenclature guidelines recommend that non-nuclear patterns should also be reported as 
a positive ANA. 
 
 
Significance and Innovations 
• This is the first study to examine the prevalence of anti-cellular antibody-negativity defined as 
the absence of any intracellular indirect immunofluorescence (IIF) staining in a large SLE 
cohort at inception. 
• In newly diagnosed SLE, 6.2% (71/1137) of patients were anti-cellular antibody-negative and 
1.5% (17/1137) had an isolated cytoplasmic and mitotic pattern (CMP). Therefore, among these 
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88 patients, 20% (17/88) would be "misclassified" as ANA negative under the traditional 
definition, when they in fact have antibodies directed against a variety of CMP targets.  
• Anti-cellular antibody-negativity was more likely in those of older age, of Caucasian 
race/ethnicity, or on high dose glucocorticoids and less likely in those on immunosuppressants. 
Longitudinal data is needed to assess how anti-cellular antibody status is influenced by the 
disease course and therapy.  
 
Autoantibodies directed against nuclear (anti-nuclear antibodies, ANA) and other 
intracellular autoantigens are a serological hallmark of systemic lupus erythematosus (SLE) and other 
ANA-associated rheumatic diseases (AARD), such as systemic sclerosis, mixed connective tissue 
disease, and Sjögren’s syndrome (1-3). ANA are widely regarded as an important classification 
criterion of SLE as officially recognized by both the American College of Rheumatology (ACR) (4) and 
the Systemic Lupus International Collaborating Clinics (SLICC) (5). ANA is traditionally defined as the 
presence of an indirect immunofluorescence (IIF) staining pattern localized to the nucleus, while 
isolated cytoplasmic and mitotic cell patterns (CMPs), although staining positive by IIF, are often not 
reported or classified as ANA-positive, and are not included in the ANA test reports by some 
laboratories. The International Consensus on ANA Patterns (ICAP) Committee has debated a 
suggestion  that  CMPs should be included in ‘ANA’ result reports and that there should be a change 
in terminology to anti-cellular antibodies because  CMPs are increasingly recognized as clinically 
relevant (6-8) and have implications for the diagnosis and classification of AARD (9). For instance, 
anti-ribosomal P proteins are highly specific for SLE and are associated with certain clinical and 
serological SLE features (10;11), but anti-ribosomal P antibodies may be reported as ANA-IIF 
negative because the prototypical staining pattern is localized to the cytoplasm (12). Therefore, 
ANA-IIF exhibits limited sensitivity for the detection of anti-ribosomal P antibodies (13). However, 
even after debate it was appreciated that current disease classification criteria are predicated on a 
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more traditional definition of ANA and that jurisdictional precedents (i.e. reimbursement fee 
structures only allow reporting of classical ANA results), it was concluded that the reclassification of 
ANA to include CMP should be delayed (9). 
Inclusion of these additional CMPs in the ANA test results would likely help minimize 
misclassification of SLE patients and the prevalence of anti-cellular antibody-negative SLE (i.e., the 
complete absence of any intracellular IIF staining patterns) will accordingly be decreased (12). The 
exact prevalence of ANA-negative SLE using the traditional definition (i.e., absence of IIF staining 
localized only to the nucleus) has been reported to range from 1 to 28% (14-16) (reviewed in (17)). A 
recent systematic review and meta-analysis of 64 studies reported that an ANA of 1:80 was highly 
sensitive at 97.8% (95% confidence interval (CI): 96.8-98.5%), but not specific (74.7% [95% CI: 66.7-
81.3%]) for SLE (18). Pisetsky et al. (14) compared different commercial ANA assays, including the 
HEp-2000 substrate, in an established SLE cohort and demonstrated significant variation in 
frequencies of ANA-positivity that ranged from 77.7% to 95.1%. In these studies, there are several 
factors (laboratory performance, study design, and clinical) that could influence the ANA results.  
Laboratory performance factors could include ANA kit selected, the definition of an ANA (i.e., 
whether it includes isolated CMPs), the ANA IIF screening dilution chosen, and technical errors such 
as variable substrate sensitivity and specificity for the detection of autoantibodies directed against 
DNA, SSA/Ro60, Ro52/TRIM21, ribosomal P and other intracellular autoantigens.  The prevalence of 
ANA-positivity is also likely impacted by whether it was measured cross-sectionally or longitudinally 
along the disease course.  ANA status is also potentially influenced by level of disease activity, 
concurrent treatment with glucocorticoids and other immune modulating drugs, and persistent 
proteinuria leading to renal immunoglobulin loss (2;9;15;19;20).    
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The purpose of this study was to examine the prevalence of anti-cellular antibody-negative 
(no intracellular IIF pattern) in a large international SLE inception cohort and to assess demographic, 
clinical, or other autoantibody characteristics associated with these redefined subgroups of SLE 
patients. 
 
MATERIALS AND METHODS 
 
Study Design and Setting 
This study was conducted using data and patient sera collected by the SLICC, a network of 53 
investigators in 43 academic medical centers in 16 countries (21-23). Between 1999 and 2011, SLICC 
investigators enrolled patients fulfilling the ACR Classification Criteria for definite SLE (4) within 15 
months of diagnosis. The study was approved by the Institutional Review Board at each participating 
site and complied with the Helsinki Declaration.  
 
Anti-cellular Antibody by Indirect Immunofluorescence assay (IIF) 
The earliest available serum at enrolment from each patient was analyzed at Mitogen Advanced 
Diagnostic Laboratory (University of Calgary, Calgary, Alberta, Canada). Aliquots of the anonymized 
SLE sera obtained from the central SLICC biobank were stored at -80oC until required for 
immunoassays. The IIF immunoassay was initially performed at a screening dilution of 1/160 (24) 
using HEp-2000 cell substrate (ImmunoConcepts, Sacramento, CA, USA) and fluorescein (FITC) 
conjugated to anti-human IgG (H + L) according to the manufacturer’s instructions. IIF results were 
read by technologists with >10 years of experience at Mitogen Advanced Diagnostics as previously 
described (25). The HEp-2000 substrate has been transfected with the SSA/Ro60 cDNA, which is then 
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overexpressed in the cells, as an approach to intentionally increase the detection of anti-SSA/Ro60 
autoantibodies, thereby increasing the sensitivity of this substrate (25;26).  The results performed at 
a single center (Mitogen) were used for the ANA analysis in this study because the ANAs performed 
at each regional site had a wide variation in testing parameters (date of test performance, serum 
screening dilutions, test kits and protocols, microscopes, readers, etc.) and hence were not 
comparable across sites.  For the purposes of this study, patients were divided into three groups 
depending on their anti-cellular antibody IIF patterns: 1) ANA-positive (presence of nuclear IIF or 
mixed nuclear and CMP staining), 2) anti-cellular antibody-negative (no intracellular staining 
detected), and 3) isolated CMP staining. 
 
Detection of Anti-dsDNA and Other Autoantibodies  
All samples were also tested for the presence of anti-dsDNA antibodies by chemiluminescence 
immunoassay (CIA: QUANTA Flash, Inova Diagnostics Inc., San Diego, CA, USA) as previously 
described (27) using a cut-off of 70 IU/mL established in accord with the SLICC Classification Criterion 
for anti-dsDNA positivity, which requires that the cutoff for the anti-dsDNA antibody level be above 
laboratory reference range (or >2-fold the reference range if tested by ELISA) (5).   
 
Antibodies to PCNA, ribosomal P, recombinant Ro52/TRIM21, native SSA/Ro60, SSB/La, Sm, and U1-
RNP were detected using the extractable nuclear antigen (ENA) FIDIS Connective Profile kit 13 
addressable laser bead immunoassay (ALBIA: TheraDiag, Paris, France) on a Luminex 200 flow 
luminometer (Luminex, Austin, TX, USA) according to the manufacturer’s instructions and read on a 
Luminex 200 system using the MLX-Booster software. Other autoantibodies such as IgG anti-
cardiolipin, IgG anti-β2 glycoprotein 1, and lupus anticoagulant were measured in a central 
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laboratory as previously described (28). ANA IIF patterns were classified according to the new ICAP: 
http://www.anapatterns.org/index.php) (9). 
 
Clinically Defined Samples 
Demographic and clinical data were collected at enrollment and included age at diagnosis, sex, post-
secondary education, disease duration, race/ethnicity, smoking, alcohol use, hypertension, nephritis 
at enrollment, proteinuria at enrollment (≥ 3g/day), ACR Classification Criteria fulfilled (total and 
individual), SLEDAI-2K (global score and organ system scores), and medication use (glucocorticoids, 
high dose glucocorticoids (any pulse steroid or prednisone ≥ 40mg/day), anti-malarials, and 
immunosuppressive agents including biologics) at or prior to cohort enrollment (Supplemental Table 
1).  
 
Statistical Evaluation 
Statistical analysis was performed using Stata 14.1 (StataCorp, College Station, TX, USA).  A three-
way comparison between ANA-positive versus anti-cellular antibody-negative versus isolated CMP 
patients was performed. Univariable and multivariable logistic regression analyses were used to 
examine potential predictors of the odds of being anti-cellular antibody-negative versus being ANA-
positive or having an isolated CMP.  As a secondary analysis, three additional univariable and 
multivariable logistic regressions were performed: 1) anti-cellular antibody-negative versus ANA-
positive, 2) isolated CMP versus ANA-positive, and 3) isolated CMP versus anti-cellular antibody-
negative.   
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Potential univariable predictors included demographic, clinical, and serological data listed above. For 
the most informative multivariable model, only statistically significant predictors at the 95% CI were 
included, after eliminating all other potential predictors individually, starting with the least likely to 
be associated with the outcome.  
 
RESULTS 
Cohort demographic, clinical, and serologic characteristics 
The baseline demographic, clinical, and serologic characteristics of the three serological groups: 1) 
ANA-positive, 2) anti-cellular antibody-negative, and 3) isolated CMP, are shown in Table 1. Overall, 
1137 patients had sera available; their mean age at diagnosis was 35.1 years (standard deviation 
(SD) 13.5) (median 33 years), 89.9% were female, 66.7% (724/1085) had obtained post-secondary 
education, mean disease duration was 0.46 years (SD 0.35), and 45.2% (511/1130) were not of 
Caucasian race/ethnicity. Three hundred and twelve of 1084 (29%) of the cohort had lupus nephritis 
at enrollment, the mean global SLEDAI-2K was 5.3 (SD 5.3), and 80.3% (913/1137) had a history 
(either at or prior to enrollment) of glucocorticoid use, 73.6% (837/1137) of antimalarial use, and 
42.7% (485/1137) of immunosuppressant use including four patients who had received biologics 
(rituximab only).  
 
Nuclear and CMP anti-cellular antibody IIF patterns 
The distribution of patients based on IIF staining patterns and specificities is shown in Supplemental 
Figures 1 and 2.  1049/1137 (92.3%) were ANA-positive which included 877 isolated nuclear (77.1%) 
and 172 mixed nuclear patterns and CMP (15.1%). 71/1137 (6.2%) were anti-cellular antibody-
negative (i.e. no detectable IIF staining), and 17/1137 (1.5%) had an isolated CMP. Therefore 7.7% 
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were either anti-cellular antibody-negative or had isolated CMP. Isolated CMP and their related ICAP 
designations included 41.2% (7/17) cytoplasmic dense fine speckled (AC-19), 23.5% (4/17) 
cytoplasmic fine speckled (AC-20), 5.9% (1/17) cytoplasmic discrete dots (AC-18), 5.9% (1/17) mitotic 
chromosomal envelope  (AC-28), and 23.5% (4/17) mixed CMP (ICAP does not have a pattern 
designation for mixed patterns at this time). 
 
 Comparison of isolated CMP with ANA-positive and anti-cellular antibody-negative and 
comparison of ANA-positive and anti-cellular antibody-negative 
Patients with isolated CMPs were not clinically or serologically different from ANA-positive or anti-
cellular antibody-negative patients for most variables (Table 1). In contrast, ANA-positive patients 
were markedly different from anti-cellular antibody-negative patients in terms of age at diagnosis 
(34.7 versus 40.9 years), race/ethnicity (higher proportion of Asians, African descendants, but fewer 
of Caucasian race/ethnicity, disease activity (SLEDAI-2K, 5.4 versus 4.1), use of 
immunosuppressants at or prior to enrollment (43.7% versus 23.9%), and frequency of SLE-related 
autoantibodies.  Interestingly, despite a negative anti-cellular antibody IIF on HEp-2000 substrate, 
some SLE-related autoantibodies were still detected, notably anti-dsDNA by CIA (11.3%), and anti-
Ro52/TRIM21 (21.1%), anti-SSA/Ro60 (22.5%), and anti-U1RNP by ALBIA (11.3%).  
 
Multivariable analysis of anti-cellular antibody-negative patients versus ANA-positive patients 
combined with isolated CMP patients 
As the isolated CMP group did not differ from the ANA-positive or anti-cellular antibody-negative for 
most variables, we chose to combine the isolated CMP with the ANA-positive for the primary 
multivariable analysis.  In the primary multivariable analysis (Table 2), patients who were older (OR 
per year 1.02 [95% CI: 1.00, 1.04]), of Caucasian race/ethnicity (OR 3.53 [95% CI: 1.77, 7.03]), or 
were on high doses of glucocorticoids at or prior to enrollment (OR 2.39 [95% CI: 1.39, 4.12]) were 
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more likely to be anti-cellular antibody-negative. Patients who were on immunosuppressants at or 
prior to enrollment (OR 0.35 [95% CI: 0.19, 0.64]) or with anti-SSA/Ro60 (OR 0.41 [95% CI: 0.23, 
0.74]) or anti-UI-RNP (OR 0.43 [95% CI: 0.20, 0.93]]) were less likely to be anti-cellular antibody-
negative. 
 
Multivariable analysis of anti-cellular antibody-negative versus ANA-positive, isolated CMP versus 
ANA-positive, and isolated CMP versus anti-cellular antibody-negative 
In the secondary multivariable analysis comparing the odds of being anti-cellular antibody-negative 
versus being ANA-positive, the predictors were identical to those in the multivariable analysis of the 
anti-cellular antibody-negative patients versus the ANA-positive combined with the isolated CMP 
patients (Supplemental Table 2). 
 
In secondary multivariable analyses comparing the odds of being isolated CMP versus ANA-positive 
or being isolated CMP versus anti-cellular antibody-negative, patients who had not attained post-
secondary education or were hypertensive were more likely to be isolated CMP positive 
(Supplemental Tables 3 & 4). 
 
DISCUSSION 
This is the first study of ANA-IIF in a large SLE inception cohort redefining negative ANA as 
the absence of any intracellular IIF staining, which we referred to as anti-cellular antibody negative. 
Traditionally, ANA-negative referred only to the absence of any IIF staining localized to the nucleus. 
This is an important consideration, especially for AARD such as SLE where the ANA test has a central 
role in establishing the diagnosis. The need to clarify this issue is exigent as it is currently under 
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international review (9) and the state of nomenclature uncertainty is the source of variability in ANA 
definitions and related clinical reports by different laboratories. Some laboratories do not report 
CMP staining whereas others provide two reports: one that specifies nuclear staining patterns and 
titers and another that indicates if CMP staining is present.   In the broader definition of ANA test 
results, the inclusive definition of ANA and CMP is more accurately referred to as anti-cellular 
antibody (1;9;29). However, because the ANA rubric is embedded in historical and scientific 
literature, the anti-cellular antibody terminology is held in abeyance until wider consensus and 
clinician education is achieved (3;9;29). The results of this study provide some insight into the 
potential diagnostic and clinical implications for SLE patients as a consequence of changing the 
definition of ANA to the wider anti-cellular antibody paradigm. 
In our analysis of patients enrolled in the SLICC inception cohort, we demonstrated that the 
prevalence of ANA-negative SLE by routine IIF on a HEp-2000 substrate at a serum dilution of 1/160 
was 7.7% (88/1137). However, if isolated CMPs (1.5%, 17/1137) were subsequently excluded from 
the ANA-negative pool of 88 patients, the prevalence of anti-cellular antibody-negative SLE would 
decrease to 6.2% (71/1137). Accordingly, amongst these 88 ANA-negative patients, nearly one in five 
is “misclassified” as ANA-negative when they in fact have antibodies directed against a variety of 
CMP targets (8). Therefore, clinicians should be aware of which approach their laboratory employs 
for routine ANA-IIF testing, because some patients with a high pre-test probability of AARD may 
have a negative ANA test when in fact it should be regarded as positive if CMP staining is present.  
In our study, SLE patients with isolated CMP could not be readily differentiated from ANA-
positive and anti-cellular antibody-negative patients based on clinical or conventional serologic 
features. These results must be interpreted cautiously however given the small sample size (n=17) of 
patients with isolated CMP.  In contrast, there were many differences between the anti-cellular 
antibody-negative and ANA-positive patients, consistent with the current literature indicating ANA-
negative SLE follows a more benign clinical course characterized by photosensitive skin rashes and 
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arthritis (19;30;31). We demonstrated in the SLICC cohort that anti-cellular antibody-negative 
patients were older (40.9 versus 34.7 years) and a higher proportion were of Caucasian 
race/ethnicity (84.5% versus 52.4%). Further, anti-cellular antibody-negative patients compared to 
ANA-positive patients had a lower global SLEDAI-2K score (4.1 versus 5.4), less frequent use of 
immunosuppressants at or prior to enrolment (23.9% versus 43.7%), and a decreased likelihood of 
having multiple SLE-associated autoantibodies, including anti-dsDNA (11.3% versus 28.4%).  These 
observations likely relate to earlier onset of more aggressive, severe disease in non-Caucasian 
patients who tend to be ANA-positive, corroborating previous studies demonstrating higher disease 
activity in non-Caucasian SLE patients (32;33).   
When the anti-cellular antibody-negative patients were compared to the isolated CMP 
combined with the ANA-positive patients, all the above observations regarding anti-cellular 
antibody-negative versus ANA-positive patients persisted in the univariable analysis.  However, in 
the multivariable analysis, slight differences were observed.  Older age and Caucasian race/ethnicity 
remained associated with a greater likelihood of being anti-cellular antibody-negative and high dose 
glucocorticoids now became associated with a greater likelihood of being anti-cellular antibody-
negative; immunosuppressant medications (at or prior to enrolment) and certain autoantibodies 
remained associated with a lower likelihood of being anti-cellular antibody-negative. Our finding 
that high dose glucocorticoids are associated with a higher likelihood of anti-cellular antibody-
negativity may be attributable to glucocorticoids influencing ANA status (34).   However, this is 
merely speculation as we have no data on ANA status prior to the baseline assessment. Patients on 
other types of immunosuppressants (i.e. methotrexate, azathioprine, mycophenolate mofetil) were 
less likely to be anti-cellular antibody-negative, perhaps due to a different effect on B cell responses 
(35;36).  Further, immunosuppressants are potentially a proxy for elements of disease activity that 
are not measured through the other clinical variables included in the regression.  Interestingly, in 
univariable analysis, all four patients treated with rituximab (data not shown) were anti-cellular 
antibody-negative (OR 11.54 [95% CI: 2.00, 66.74]). As suggested in a review by Cross et al. (15), 
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previous literature on ANA-negative SLE has been poor at documenting concurrent therapies: in that 
review and commentary, only five of 164 (3%) patients had data on medications during ANA testing. 
This highlights the need to review concurrent medications and consider other known confounders 
such as proteinuria, as we have done.   
The ANA of our cohort was tested on the HEp-2000 substrate, which has been engineered to 
intentionally increase the detection of anti-SSA/Ro60, thereby lowering the prevalence of ANA-
negative SLE (25;26;37;38).  Up to two thirds of patients with mild SLE and persistently negative ANA 
tested on rodent liver substrate have been serologically linked to SLE due to precipitating 
autoantibodies to SSA/Ro60 (31). These findings are particularly relevant to the clinical subset of SLE 
that have subacute cutaneous SLE and/or features of secondary Sjögren’s syndrome (39).  However, 
even with the technical improvements, such as HEp-2000 substrates, our study and others (reviewed 
in (20)) indicate a persistent gap in autoantibody detection by HEp-2 substrates, which in the present 
study included anti-SSA/Ro60 and even anti-dsDNA. For example, 22.5% of the anti-cellular 
antibody-negative SLE patients in our study still had anti-SSA/Ro60 antibodies using extractable 
nuclear antigen testing; 11.3% of our anti-cellular antibody-negative patients had anti-dsDNA by CIA.  
Our observations are consistent with a recent study showing that there is significant lack of 
agreement between positive results using a conventional multiplex array technology and the IIF on 
HEp-2 cells (40).   
Significant variation in the frequencies of positive ANA in well characterized SLE patients 
have been reported  (15;17;18;41); some of this variation relates to the performance of  different 
HEp-2 assay kits (14). In this study, we used a serum dilution of 1/160 to maximize specificity of the 
test at the possible expense of sensitivity (24). When the IIF test was repeated at a serum dilution of 
1/80 on 67/71 of the available anti-cellular antibody-negative samples, we observed that 17/67 
(25.4%) became clearly positive for nuclear and/or CMP staining (detailed data not shown). In a 
cross-sectional study, it was reported that only 76% of unselected SLE sera had a positive ANA, but a 
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relatively high serum dilution of 1/200 was used (16). Taken together, this suggests that newer 
multiplexed autoantigen array technologies might be considered in the future as a replacement for 
the ANA IIF.  
The presence of anti-dsDNA in ANA-negative SLE patients has been reported by others 
((42;43) and references therein). These patients were reported to have more severe complications 
including nephritis (44), dystrophic calcification (45), or severe autoimmune neutropenia (46). Thus, 
the detection of anti-dsDNA antibodies even in ANA-negative cases is still important and may aid in 
risk assessment for clinical complications. Furthermore, the anti-dsDNA repertoire is diverse, such 
that there is no current anti-dsDNA assay that is able to detect all of the subpopulations of anti-
dsDNA autoantibodies (47). Overall, the reports of anti-dsDNA positive/ANA-negative sera found in 
the literature provide evidence that not all anti-dsDNA antibodies are detected on conventional HEp-
2 substrates and that unique dsDNA epitopes may be missed by HEp-2 IIF screening tests. 
Biomarkers such as autoantibodies and a variety of immune-related and inflammation-
related molecules can appear years prior to clinical symptoms and/or the diagnosis of SLE and can 
accrue over time [(40) and reviewed in (48)]. Therefore, longitudinal studies are needed to evaluate 
the serologic status of anti-cellular antibody-negative and isolated CMP patients over time and 
whether it varies with disease activity, damage accrual, therapeutic interventions, and/or specific 
substrate assays. Even among ANA-negative patients with lupus nephritis, it can take up to 10 years 
to seroconvert from ANA-negative to positive (17;40). Some patients may only have detectable 
positive serology when there is uncontrolled disease activity due to loss of self-tolerance from 
chronic auto-reactivity of T and B cells (17). 
There are some limitations to our study. First, the similarities reported between CMP and 
ANA-positive patients are likely confounded by the high proportion of ANA-positive patients also 
expressing CMP (21.5%). Overall, approximately 17% of patients in the entire cohort expressed CMP 
(189/1137) but the majority (91.0%, 172/189) were seen in conjunction with nuclear IIF patterns. As 
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a result, the isolated CMP group size (n=17) was small, limiting the statistical power of our analysis. 
We also did not perform statistical correction for multiple comparisons, which is consistent with the 
exploratory and hypothesis generating aspect of our study. Additionally, we evaluated ANA status 
only at disease inception, but we have the capacity with this inception cohort, where data and sera 
are collected longitudinally, to evaluate ANA status and factors influencing it over the disease 
course.  
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Table 1. Baseline demographic, clinical and autoantibody profiles of ANA-positive (presence of 
any nuclear IIF pattern), anti-cellular antibody (ACA)-negative (no IIF pattern), and isolated 
cytoplasmic/mitotic (CMP) groups 
  ANA+ ACA- Isolated 
CMP# 
Difference (95% CI) 
 
n=1049 n=71 n=17 
ANA+ and 
ACA- 
ANA+ and 
CMP 
ACA- and CMP 
Demographics       
Age at diagnosis, year, 
mean  
34.7* 40.9* 35.8 -6.2 (-9.4, -2.9) -1 (-7.5, 5.4) 5.1 (-2.4, 12.7) 
Female, % 89.7 90.1 100 -0.4 (-7.6, 6.7) -10.3 (-24.8, 4.2) -9.9 (-24.2, 4.5) 
Post-secondary education, 
% attended 
66.7* 76.1† 31.3†* -9.5 (-20.1, 1.2) 35.4 (12.5, 58.3) 44.9 (20, 69.8) 
Disease duration, years 0.47 0.42 0.35 0.05 (-0.03, 0.14) 0.12 (-0.05, 0.29) 0.07 (-0.12, 0.25) 
Race/ethnicity, %        
Asian 23.2* 4.2* 11.8 19 (13.7, 24.3) 11.5 (-4.1, 27) -7.5 (-23.6, 8.5) 
African descendant 16.2* 7.0* 5.9 9.2 (2.8, 15.5) 10.3 (-1.1, 21.7) 1.2 (-11.5, 13.8) 
Hispanic 3.4 2.8 0 0.5 (-3.5, 4.5) 3.4 (-5.2, 11.9) 2.8 (-1, 6.7) 
Caucasian 52.4†* 84.5* 76.5† -32.1 (-41.1, -23.2) -24.1 (-44.5, -3.7) 8 (-13.8, 29.9) 
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Other 4.8 1.4 5.9 3.4 (-1.6, 8.4) -1.1 (-12.3, 10.2) -4.5 (-16, 7) 
Smoking status, %       
Current smoker 15.1 21.9 18.8 -6.8 (-17.1, 3.6) -3.7 (-22.9, 15.6) 3.1 (-18.5, 24.8) 
Former smoker 21.1 26.6 25 -5.5 (-16.6, 5.6) -3.9 (-25.3, 17.5) 1.6 (-22.3, 25.4) 
High alcohol use, %  1.5 1.5 0 0 (-3, 3) 1.5 (-4.6, 7.5) 1.5 (-4.7, 7.6) 
Hypertension, % 32.6* 29.6† 58.8†* 3 (-8, 14) -26.2 (-49.8, -2.7) -29.2 (-54.9, -3.6) 
Nephritis at enrollment, % 28.7 26.6 50 2.1 (-9, 13.3) -21.3 (-46, 3.4) -23.4 (-50.2, 3.3) 
Proteinuria at enrollment, % 4.5 3.3 12.5 1.2 (-3.4, 5.9) -8 (-24.3, 8.3) -9.2 (-26, 7.6) 
# ACR criteria, mean 4.8 4.7 4.7 0.1 (-0.1, 0.4) 0.1 (-0.4, 0.6) 0 (-0.5, 0.5) 
SLEDAI-2K score, mean 5.4* 4.1* 5.4 1.3 (0, 2.6) 0 (-2.7, 2.6) -1.3 (-3.8, 1.1) 
Neurological 0.3 0.3 0 -0.1 (-0.5, 0.3) 0.3 (-0.5, 1) 0.3 (-0.5, 1.2) 
Mucocutaneous 1.1 1 1.3 0.1 (-0.4, 0.5) -0.1 (-1.1, 0.8) -0.2 (-1, 0.6) 
Musculoskeletal 0.8 0.7 1.3 0.1 (-0.3, 0.5) -0.4 (-1.3, 0.4) -0.5 (-1.4, 0.4) 
Renal 1.4 0.7 1.8 0.7 (-0.1, 1.5) -0.4 (-2, 1.2) -1.1 (-2.5, 0.4) 
Serositis 0.1 0.1 0 0 (-0.1, 0.1) 0.1 (-0.1, 0.3) 0.1 (-0.2, 0.4) 
Constitutional 0 0 0 0 (0, 0.1) 0 (-0.1, 0.1) 0 (0, 0.1) 
Immunological 1.6* 1.1* 1.1 0.5 (0.1, 0.9) 0.5 (-0.4, 1.3) 0 (-0.9, 0.8) 
Hematological 0.1 0 0 0.1 (0, 0.1) 0.1 (-0.1, 0.3) 0 (-0.1, 0.1) 
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Medications, % ever used       
Glucocorticoids 80.6 74.6 82.4 6 (-4.4, 16.4) -1.7 (-20, 16.6) -7.7 (-28.5, 13.1) 
High dose of 
glucocorticoids 
42.3 46.5 58.8 -4.2 (-16.1, 7.8) -16.5 (-40.1, 7.1) -12.3 (-38.5, 13.8) 
Antimalarials 74.3 69 52.9 5.2 (-5.8, 16.3) 21.3 (-2.6, 45.2) 16.1 (-10, 42.1) 
Immunosuppressants 43.7* 23.9†* 58.8† 19.7 (9.3, 30.1) -15.2 (-38.7, 8.4) -34.9 (-60.3, -9.5) 
Autoantibodies, %       
dsDNA  28.4* 11.3* 17.7 17.2 (9.3, 25) 10.8 (-7.5, 29.1) -6.4 (-25.9, 13.2) 
PCNA 7.3 1.4 11.8 5.9 (-0.2, 12) -4.4 (-19.8, 11) -10.4 (-25.9, 5.2) 
Ribosomal-P 16.1* 5.6* 11.8 10.5 (4.7, 16.3) 4.3 (-11.1, 19.8) -6.1 (-22.4, 10.1) 
Ro52/TRIM21 35.9* 21.1* 23.5 14.8 (4.9, 24.7) 12.4 (-8, 32.8) -2.4 (-24.7, 19.9) 
SSA/Ro60 47.3* 22.5* 29.4 24.7 (14.6, 34.9) 17.9 (-4, 39.7) -6.9 (-30.6, 16.9) 
SSB/La 15.9* 5.6* 11.8 10.3 (4.5, 16.1) 4.2 (-11.3, 19.6) -6.1 (-22.4, 10.1) 
Sm 24.7* 5.7* 11.8 19 (12.9, 25) 12.9 (-2.6, 28.5) -6.1 (-22.3, 10.2) 
U1-RNP 32.4* 11.3* 11.8 21.1 (13.3, 29) 20.6 (-1.7, 43) -0.5 (-17.5, 16.5) 
Lupus Anticoagulant 20.8 20.6 6.7 0.1 (-10.2, 10.5) 14.1 (-6.5, 34.7) 14 (-2.1, 30.1) 
Anti-cardiolipin 12.6 11.1 12.5 1.5 (-6.6, 9.5) 0.1 (-16.3, 16.4) -1.4 (-19.4, 16.6) 
Anti-ß2glycoprotein1 15 15.9 12.5 0.8 (-10.1, 8.5) 2.5 (-13.8, 18.9) 3.4 (-15.2, 21.9) 
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#Some predictors had a small portion of missing values - where these occurred, the observations were excluded from the 
relevant analysis. In particular, for the small group of patients with isolated CMP, the data included 1 missing value for 
education, smoking status, nephritis, proteinuria, #ACR criteria, anti-cardiolipin, anti-beta2glycoprotein 1, and 2 missing 
values for high alcohol use and lupus anticoagulant 
 
†, *, or in combinaƟon: values with the same superscript are significantly diﬀerent from each other, i.e. †* is diﬀerent 
from† and *, but † and *are not. 
Abbreviations: ACR, American College of Rheumatology; ANA, anti-nuclear antibody; dsDNA, double stranded DNA; IIF, 
indirect immunofluorescence; PCNA, proliferating cell nuclear antigen; RNP, ribonucleoprotein; SLE, systemic lupus 
erythematosus; SLEDAI, SLE disease activity index; Sm, Smith (U2-U6 RNP); SSA, Sjögren’s syndrome antigen A; SSB, 
Sjögren’s syndrome antigen B; TRIM 21, tripartite motif 21; yr, years.  
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Table 2. Univariable and multivariable analysis of demographic, clinical, and serologic profiles of 
anti-cellular antibody(ACA)-negative versus ANA-positive combined with isolated 
cytoplasmic/mitotic patterns (CMP)  
 
  
ACA- vs ANA+ or Isolated CMP 
Univariate model 
Odds ratio 
95% CI 
Multivariate model  
Odds ratio 
95% CI 
Demographics     
Age at diagnosis, year 1.03 (1.01, 1.05)* 1.02 (1.00, 1.04)* 
Female, % 1.03 (0.46, 2.31)   
Post-secondary educ., % attended 1.63 (0.92, 2.91)   
Disease duration, years 0.66 (0.32, 1.34)   
Race/ethnicity, %     
Asian 0.15 (0.05, 0.47)*   
African descendants 0.40 (0.16, 1.00)*   
Hispanic 0.85 (0.20, 3.60)   
Caucasian 4.88 (2.54, 9.38)* 3.53 (1.77, 7.03)* 
Other 0.28 (0.38, 2.07)   
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Smoking status, %
  Current smoker 1.57 (0.85, 2.90) 
Former smoker 1.35 (0.76, 2.39)
High alcohol use 1.04 (0.14, 8.00)   
Hypertension 0.85 (0.50, 1.44)   
Nephritis at enrollment, %  0.88 (0.50, 1.56)   
Proteinuria at enrollment, % 0.70 (0.17, 2.95)  
# ACR criteria, mean 0.89 (0.69, 1.14)   
SLEDAI-2K score, mean 0.94 (0.89, 1.00)* 
  
 Neurological 1.03 (0.90, 1.18)
 Mucocutaneous 0.98 (0.85, 1.12) 
 Musculoskeletal 0.97 (0.84, 1.14) 
 Renal 0.91 (0.81, 1.01) 
 Serositis 1.12 (0.72, 1.75) 
 Constitutional 0.37 (0.05, 2.73)
 Immunological 0.82 (0.69, 0.96)* 
 Hematological 0.41 (0.13, 1.27)
Medications, % ever using     
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Glucocorticoids 0.71 (0.40, 1.23)   
High doses of glucocorticoids 
Antimalarials 
1.17 (0.72, 1.90) 
0.79 (0.47, 1.32) 
2.39 (1.39, 4.12)* 
Immunosuppressants/biologics 0.40 (0.23, 0.70)* 0.35 (0.19, 0.64)* 
   
Autoantibodies, %     
        dsDNA  0.32 (0.15, 0.68)*  
        PCNA 0.18 (0.02, 1.30)   
Ribosomal-P 0.31 (0.11, 0.87) *   
Ro52/TRIM21 0.48 (0.27, 0.86) *   
SSA/Ro60 0.33 (0.19, 0.58) * 0.41 (0.23, 0.74) * 
SSB/La 0.32 (0.11, 0.88) *   
Sm 0.19 (0.07, 0.52) *   
U1-RNP 0.27 (0.13, 0.57) * 0.43 (0.20, 0.93)* 
Lupus Anticoagulant 1.00 (0.54, 1.88)
Anti-cardiolipin 0.87 (0.39, 1.95)   
Anti-ß2glycoprotein1 1.07 (0.53, 2.15)   
*Denotes an odds ratio that is statistically significant 
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Abbreviations: ACR, American College of Rheumatology; ANA, anti-nuclear antibody; dsDNA, double 
stranded DNA; IIF, indirect immunofluorescence; PCNA, proliferating cell nuclear antigen; RNP, 
ribonucleoprotein; SLE, systemic lupus erythematosus; SLEDAI, SLE disease activity index; Sm, Smith 
(U2-U6 RNP); SSA, Sjögren’s syndrome antigen A; SSB, Sjögren’s syndrome antigen B; TRIM 21, 
tripartite motif 21; yr, years.  
 
  
